ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT03262935

Public ClinicalTrials.gov record NCT03262935. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Study identification

NCT ID
NCT03262935
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Byondis B.V.
Industry
Enrollment
437 participants

Conditions and interventions

Interventions

  • (vic-)trastuzumab duocarmazine Drug
  • Physician's choice Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 14, 2017
Primary completion
Mar 30, 2021
Completion
Jun 29, 2022
Last update posted
Oct 18, 2023

2017 – 2022

United States locations

U.S. sites
23
U.S. states
15
U.S. cities
20
Facility City State ZIP Site status
Southern Cancer Center Mobile Alabama 36608
Arizona Clinical Research Center Tucson Arizona 85715
Moores UCSD Cancer Center San Diego California 92093
Woodlands Medical Specialists Pensacola Florida 32503
Rush University Medical Center Chicago Illinois 60612
Cancer Center of Kansas Wichita Kansas 67214
University of Maryland Greenebaum Cancer Center Baltimore Maryland 21144
Greater Baltimore Medical Center Baltimore Maryland 21204
Henry Ford Hospital Detroit Michigan 48202
Saint Luke's Hospital of Kansas City Kansas City Missouri 64111
FirstHealth Outpatient Cancer Center Pinehurst North Carolina 28374
Toledo Clinic Cancer Center Toledo Ohio 43623
Northwest Cancer Specialists Portland Oregon 97213
Magee-Womens Hospital of UPMS Pittsburgh Pennsylvania 15213
Texas Oncology PA (Texas Oncology-Dallas Presbyterian Hospital) Dallas Texas 75231
Texas Oncology- Baylor Charles A. Sammor Dallas Texas 75246
Texas Oncology - Denton South Denton Texas 76210
Texas Oncology-Memorial City Houston Texas 77024
Baylor College of Medicine Houston Texas 77030-34011
Texas Oncology-San Antonio Northeast San Antonio Texas 78217
Texas Oncology-Tyler Tyler Texas 75702
Virginia Cancer Specialists, PC Fairfax Virginia 22031
Virginia Oncology Associates Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03262935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 18, 2023 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03262935 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →